Background: Benzodiazepines (BZDs) are very often inappropriately prescribed drugs. The aim of this study is to analyse physicians' prescribing patterns for BZD in Republic of Srpska, and to assess to what extent primary diagnosis determine the dose and the length of use of BZDs. Methods: A retrospective analysis of the physicians' prescription habits based on the database of Family Medicine Information Systems of Republic of Srpska, as well as on data from patient's medical record were performed. Patients' socio-demographic and clinical characteristics, including the data on the type and dose of BZDs prescribed, were recorded and evaluated. Results: BZDs were mostly prescribed for anxiety disorders (30.05%), for depressive disorders (17.54%), and for anxiety-depressive disorders (10.86%). A significant amount of BZDs was prescribed for non-psychiatric diagnoses (23.81%). Patients suffering from psychotic disorders were taking the highest dose of BZD and for the longest periods of time (p<0.001). Longer use of BZDs was in women (r=0.04, p<0.001), elderly (r=0.178, p<0.001), single people (r=0.12, p<0.001), those who live in urban areas (r=0.45, p<0.001) and those who were prescribed higher doses (r=0.213, p<0.001). Conclusion: A significant percentage of patients were using the BZDs for longer period of time than recommended. Strongest positive correlation was found between the dose and the length of use, which implies the addictive potential of BZDs. Since it has been noticed that prolonged use, or abuse is present regardless of the diagnosis, precaution is advised when prescribing BZDs even for acute diseases.
Benzodiazepines (BZDs) are agonists of the BZD receptors at the γ-amino-butyric acid A (GA-BA-A) receptor complex. The effect of stimulation of GABA receptors provides its anxiolytic, sedative, hypnotic, anticonvulsant and myorelaxant effect. 1 BZDs are used in treatment of insomnia, anxiety disorders and along with antidepressant. 2 They are also used in the treatment of terminally ill cancer patients. 3 According to current guidelines the use of BZD should be limited to shorter use (up to 4 weeks) to minimize the risk of adverse reactions (e.g. dependence or withdrawal symptoms). 4, 5 However, it is estimated that 3% of the general population use BZD for the period longer than 6 months in continuity. 6 The long term use of these drugs is potentially inappropriate and can cause a range of adverse side effects including cognitive and psychomotor impairment, particularly in older patients.
INTRODUCTION
Most authors agree that use of BZDs for longer than 6 months suggests addiction. Abuse of opiates and BZDs is often coinciding. 8 Longer use of BZDs, especially in the elderly, is correlated with frequent falls, moderate risk of all causes of death and dementia. [8] [9] [10] [11] [12] Despite lack of recommendations, BZDs are often used for treatment of pain and somatic disorders. Furthermore, there are even relative contraindications for use of BZDs in patients suffering from schizophrenia, and in patients with psychotic disorders BZDs should only be used for very short sedation and calming down of acutely agitated patients. 13, 14 The aim of this study is to evaluate physicians' habits in prescribing of BZD in the primary health care settings of Republic of Srpska, and to assess to what extent the primary diagnosis determines the dose and the length of use of BZDs. 
METHODS

RESULTS
Retrospective cross-sectional study was conducted. Doctors prescribing practice data in primary healthcare were collected from the Family Medicine Information Systems (WebMedic) of Republic of Srpska. Anonymity of patients was preserved. Personal medical record of each patient was coded, without data related to patients' name, initials or personal identification number. Only data of patients age and sex were available.
I. Prescription analysis
All patients that had been using BZDs from February 2011 to February 2018 were included in this study. Basic socio-demographic and clinical data such as: gender (male/female), age (years), smoking status (smoking/not smoking), place of residence (urban environment: municipality population ≥ 20,000 inhabitants / rural environment: municipality population <20,000 inhabitants), marital status (married/single), prescribing diagnosis for BZDs, existence and type of comorbidity were analysed.
For easier comparison, all diagnoses for which BZDs were prescribed are grouped as follows: (1) mixed anxiety-depressive disorder; (2) anxiety disorders; (3) depressive disorders; (4) psychotic disorders; (5) other psychiatric disorders (psychiatric diagnoses that do not fit into the first four groups); (6) Table 2 . Two thirds of the patients to whom BZDs had been prescribed were women. Average age of patients was 60, with only 1/10 of patients being younger than 40, and half of the patients aging 41-65. Two thirds of patients were single. Again, two thirds of patients lived in urban areas. Of the sample of 515 patients, 3/4 were non-smokers, while 139 were smokers (26.99%). (Table 2 ). Diagnosis had statistical impact on choice of BZDs (χ2=13747.23, p<0.001). Short-acting BZDs were most commonly prescribed for depressive and mixed anxio-depressive disorders, and least for psychotic and non-psychiatric disorders ( Figure 1 ). Intermediate-acting BZDs were most commonly prescribed for non-psychiatric and anxiety disorders, and least for psychotic disorders. Patients suffering from psychotic disorders, used long-acting BZDs (even more than intermediate-acting), and this was the only group in any category, that did not prefer intermediate-acting BZD. Patients that suffer from depressive and mixed anxiety-depressive disorders more often than other patients used different BZDs. (Figure 1 near here).
Since it was noticed that BZD had been prescribed to a significant percentage of patients based on non-psychiatric diagnosis, further analysis was conducted. Within the non-psychi-atric group of disorders musculoskeletal diseases were the most common reason for prescribing BZD (29.16%), followed by epilepsy (22.92%), hypertension (13.54%), arrhythmias (9.38%) and chest pain (6.25%). Other diseases, such as headache, vertigo, etc. were presented less often. More than 4/5 patients to whom BZDs were prescribed had one or more comorbidities. Most common comorbidity was hypertension. Patients who had more than three chronical diseases and used more than five different drugs every day were set aside to a separate category. Existence and type of comorbidity, as well as their average dose and lenght of their use is shown in Table 4 . 
DISCUSSION
The results of this study showed that BZDs were mainly prescribed to women as well as to older patients. Women have been taking BZDs almost twice as often as men, and studies from other countries showed similar results. [18] [19] [20] [21] [22] [23] [24] [25] [26] BZDs were used mainly by older patients and also for longer time compared to younger patients, which corresponds to studies from abroad that classified BZDs, specifically long-acting BZDs, as top 5 most inappropriately prescribed drugs in the elderly. 18, 20, 21, [25] [26] [27] [28] [29] [30] In terms of correlations, there was a statistically significant negative correlation between the dose of BZD and the age patients -the older the age, the smaller the daily dose. This finding is in accordance with global findings, which also state that older patients use smaller doses of BZDs, which is logical, based on the narrow therapeutic width of BZDs in the elderly population, due to lower creatinine clearance values, reduced liver functionality, polypharmacy and interaction with other drugs and reduced body weight. 21, 25, 29, 30 When it comes to marital status, nearly 60% of patients were single. That coincides with results of published studies. 29, 31 Our results show that patients from urban areas tend to use BZDs more often than those living in rural areas (70%:30%). Other studies comparing incidence of depressive and anxiety disorders showed that mood disorders occur more often in patients from urban areas compared to the rural ones. 32 Also, citizens of urban areas take BZDs for longer periods of time. [33] [34] [35] This is somewhat logical taking in consideration faster life style, noise, traffic, air pollution and other factors that citizens of urban areas are more exposed to.
The percentage of smokers in the examined sample matched the estimated percentage of smokers in Republic of Srpska. Data show that smokers use significantly larger doses of BZDs, which corresponds the data from the literature. 25 Furthermore, this study showed that there were more smokers among the users of long-acting BZDs. This is probably due to the fact that smokers are being generally more anxious, with weaker impulse control, so they need a stronger and longer-lasting anxiolytic effect. 36, 37 Based on the diagnosis, use of BZDs is expectedly high in patients with anxiety and depressive disorders, but unusually high (23.8%) in patients with non-psychiatric disorders. Some regional studies show a high trend of prescribing BZDs to hypertensive patients, but it is known from primary care practice that the trend exists in other non-psychiatric disorders (low back pain, diabetes, myalgia, headache), as was confirmed by our findings. 38, 39 One of the reasons for such a high percentage of prescribed BZDs for non-psychiatric disorders could also be the lack of care by family medicine physicians when it comes to making a diagnosis. Doctors may have thought that anxiety of the patient makes the primary disease worse, but they did not find it necessary to introduce officially into patient's record the diagnosis of anxiety or mixed mood disorder. Prescription of BZDs in mentioned indications is justified, but lenght of their use in these indications is troubling. For example, BZDs have been used for such a long time for low back pain and for anxiety-depressive disorders. Evidently, prolonged usage, or abuse, of BZDs is equally present regardless of the diagnosis.
Short-acting BZDs were most often prescribed to patients suffering from depressive and mixed anxio-depressive disorders, which is logical when taking in consideration that they have the fastest onset of therapeutic effect, and patients take them to control acute anxiety attacks. It would be logical that they are prescribed most frequently in patients with anxiety disorders as well, however intermediate-acting BZDs are most frequently prescribed in these disorders. Long-acting BZDs are most often prescribed in patients with psychotic disorders. Reason for this is probably that the agitated psychotic patient needs to be sedated for the longest period possible.
When comparing the dose and the length of use with diagnosis, it was apparent that patients with anxiety and psychotic disorders are prescribed with both highest doses and for the longest period of time, whereas patients with non-psychiatric disorders receive the smallest doses. Prescription of BZDs to patients with psychotic disorders is not in accordance with guidelines, especially during longer period of time. However, prescription of BZDs to patients suffering from schizophrenia is only justified for acute treatment of agitated patients. Same patients use BZDs for the longest periods of time, and use long-acting BZDs the most often. Patients suffering from psychotic disorders fit the only group that takes long-acting BZD more often compared to intermediate-acting ones. Length of use of BZDs in patients with psychotic disorders is totally opposite from the guidelines. Possible reasons are fear and prejudice of doctors towards these patients, and the need to calm these patients down, even though the stabilisation of mood in these patients is not achieved with use of BZDs. Larger doses in patients with depressive disorders would be justified if the length of use was shorter. In all new depressive episodes, along with an antidepressant an anxiolytic is also introduced, but it is recommended that the dose should start to decrease after three weeks until complete discontinuation of its use. Taken in consideration that this was not the case in these results, this is an example of poor prescribing practice. Both shortest length of use and smallest dose of BZDs were prescribed to patients with non-psychiatric disorders, which is logical given that these are usually temporary conditions. High blood pressure episode in acute stress reaction (which should be treated with anxiolytics) is often miscategorised as hypertension, rather than a psychiatric disorder. Worldwide studies showed that patients with sleeping disorders, dementia and depression use BZDs for longest time periods. 39, 40 Existence and type of comorbidity had no effect on lenght of use of BZDs, which is somewhat logical, considering that primary diagnosis should be a reason for shorter or longer lenght of use, not a comorbidity. Patients without comorbidities compared to those with comorbidities used higher doses, which is justified. 39 However, further analysis showed that lower dose was prescribed only to patients that suffer from cardiovascular diseases, including hypertension, and other diseases were not taken into consideration. Lack of reduction of the BZD dose, especially in patients who had more than three chronic diseases and used more than five different drugs every day is highly alarming. Unfortunately, this is also an example of poor prescribing practice, considering that interactions among drugs in polypharmacy is very often. Family doctor, as a psysician able to see the entire medical history of a patient, must take a responsibility, if necessary, for reduction of dose if psychiatrist, or other specialist, overlooked polypharmacy. 41, 42 In conclusion, a significant percentage of patients were using the BZDs for a longer time period than recommended. Strongest positive correlation was found between dose and longer use, which implies addictive potential of BZDs. Since it has been noticed that prolonged use, or abuse is present regarding the diagnosis, precaution is advised when prescribing BZDs even for acute diseases.
